Abstract: The pineal gland in humans is under both a-and b-adrenergic control, although it seems that b 1 -adrenoceptors are mainly implicated in melatonin secretion. In the present study, we evaluated the role of b-adrenergic innervation on melatonin production and its relation with the production of growth hormone (GH). Thirty-four children (15 males and 19 females, mean age 10.5 90.8 years) from the University of Granada Hospital were studied. The children were included in a protocol for the evaluation of growth delay using the propranolol+ exercise test. This standardized test allowed us to study simultaneously the role of an unspecific b-adrenergic blocker such as propranolol and of an adrenergic stimulus such as exercise on the pineal production of melatonin. Changes in plasma levels of melatonin and GH were determined at basal, 120 and 140 min after the test was applied. Hormonal determinations were carried out by commercial radioimmunoassay kits previously standardized in our laboratory. The results show a significant decrease in plasma melatonin levels at 120 and 140 min after the test (P B 0.05), whereas GH levels increased significantly at 140 min (P B 0.001). The decrease of melatonin levels was a consequence of the test, since in a control group, the circadian decay of melatonin was significantly less pronounced (PB 0.05). These data suggest an inverse relationship between melatonin and GH after the propranolol +exercise test, and the reduction in melatonin may be related to its depletion by exercise-induced oxidative stress.
Introduction
In mammals, pineal activity mainly depends on adrenergic innervation regulating both b 1 -and a 1 -adrenoceptors [Sudgen et al., 1984; Cowen et al., 1985; Hanssen et al., 1987; Santana et al., 1989] , although a 2 -adrenoceptors are also involved [Muñ oz-Hoyos et al., 2000] . Activation of b 1 -adrenoceptors takes place at night, thus inducing a nocturnal peak of melatonin, whereas a 2 -adrenoceptor activation reduces melatonin release. Melatonin synthesis induced by b 1 -adrenoceptor stimulation is further potentiated by stimulation of a 1 -adrenoceptors [Sudgen et al., 1984; McLeod and Cairncross, 1995] . In humans, it was frequently reported that blocking b 1 -and/or b 2 -adrenergic receptors suppresses melatonin secretion, although selective b 1 -adrenoceptor blocking was more specific in inhibiting pineal function [Little et al., 1996] . Propranolol caused a dose-dependent decrease in melatonin levels in both the dark and the light in normal subjects, an effect similar to the light at night [Mayeda et al., 1998 ]. Recently, the use of specific b-blocking and combined a-and b-blocking agents on melatonin production in humans has revealed that b-blockers decrease melatonin release via specific inhibition of adrenergic b 1 -receptors [Stoschitzky et al., 1999] . However, some data suggest that neither b 2 -nor b 1 -adrenoceptor agonists stimulate daytime melatonin secretion in healthy subjects [Berlin et al., 1995] and thus, the role of the b-adrenoceptors in the human pineal function remains unclear.
Exercise has been used to evaluate the role of b-adrenoceptors in the human pineal function. It has been reported that plasma melatonin increases during exercise in women [Carr et al., 1981] , although other authors did not report conclusive effects [van Cauter et al., 1993] . In animals, an unusual response of nocturnal pineal melatonin synthesis and secretion to exercise has been reported, suggesting a disparity between pineal Nacetyltransferase activity and melatonin content [Yaga et al., 1993] .
There are several data suggesting a relationship between melatonin and the hypothalamic -pituitary axis. In normal subjects, melatonin displays a normal circadian rhythm under constant routine experiments without exercise, whereas GH secretion is modulated to some extent by circadian rhythms [Uchiyama et al., 1998 ]. Melatonin production increases in some situations involving hypothalamic -pituitary dysfunction [Walker et al., 1996; Pawlikowski and Zarzycki, 1999] . In acromegaly, parameters of the nocturnal melatonin peak (area under the curve, mesor and amplitude) were significantly lower than in the controls, with an earlier acrophase [Sinisi et al., 1997] . In this situation, octreotide (an eight-chain amino acid analogue of somatostatin) administration significantly reduced GH, restoring a circadian melatonin rhythm in 50% of the patients. These data suggest a relationship between melatonin and GH secretion. In fact, exercise-induced GH secretion is enhanced by melatonin administration in healthy subjects [Meeking et al., 1999] .
The role of pineal b-adrenergic innervation on melatonin production in children is less clear than in adults. Thus, we considered it worthwhile to examine the effect of b-adrenergic manipulation on melatonin levels in children. For this, we used the propranolol+exercise test, a standard protocol used for evaluating the endogenous GH secretion in children with growth delay, on plasma melatonin and GH levels in these patients.
Materials and methods

Subjects
Due to ethical considerations, a pharmacological study as described in this paper cannot be carried out in normal children. The study was conducted on 34 pediatric patients who were accepted in the University of Granada Hospital (Granada, Spain) for an evaluation for growth delay. Informed consent was obtained from all parents and from the Hospital's Ethical Committee, according to the 1983 revised Helsinki Declaration of 1975. The clinical history, somatometric data, height prediction and analytical results suggested GH deficiency. Patients with the following selection criteria, according to Tanner and Whitehouse tables [Tanner, 1978] , were suitable candidates for the examination of pituitary function: a) height below percentile 3; b) growth rates below the 25th percentile. This group included children with near-normal height, but growth rates that were halted. Children with a growth rate below 7 cm/year before 3 years old; below 4-5 cm/year during the 3 years before puberty, and below 5.5 -6 cm/year during puberty, were considered to have an inadequate growth rate [McGillivray, 1987] ; c) delayed bone maturation, these children had a bone age at least 2 years below their chronological age. The characteristics of the 34 children selected for this study are depicted in Table 1 .
Propranolol+exercise test
This test is used to evaluate hypophyseal GH response at the University of Granada Hospital. The exercise test is a non-invasive stimulus for evaluating GH production; this test consists of ascending and descending an eight-story staircase during 20 min at normal rate. Propranolol is used in conjunction with exercise and is administered at dose of 0.75 mg/kg v.o. Propranolol was administered at 09:00 hr (basal time) and the exercise started immediately thereafter. Blood samples were taken just before propranolol administration (basal) and 120 and 140 min thereafter. According to the GH response to the applied test, the children were classified in three groups as described elsewhere [Muñ oz-Hoyos et al., 2000] (Table 1) : a) CGD (constitutional growth delay) group, consisting of 11 patients (seven males and four females); b) GLH (genetic low height) group, consisting of 14 patients (five males and nine females), and c) GHPD (growth hormone partial deficit) group, consisting of 9 patients (three males and six females). CGD and GLH groups showed a normal GH response, whereas GHPD group showed a GH response of only 50%. Three days prior to the exercise+pro-pranolol test, basal, 120 and 140 min blood samples were taken from the same children included in the three groups. Only children showing a normal GH response to exercise+propranolol test, i.e. children from CGP and GLH groups, were used for the control group.
Hormone measurements
Blood was centrifuged at 3,000g for 10 min and plasma was separated and frozen at −20°C until hormone assays. Melatonin was determined by a commercial radioimmunoassay (DLD, Diagnostika GMBH, Hamburg, Germany) and a quality control [Fernõ ndez et al., 1990] was performed with intra-and interassay coefficients of variation of 11.3 and 6.3%, respectively. The recovery of added melatonin was 84.4% and the sensitivity of the assay was 1 ng/L. Levels of GH were determined by a commercial radioimmunoassay (Sorin, Italy) with a sensitivity of 0.2 ng/mL, and intra-and interassay coefficients of variation of 3.0 and 5.1%, respectively. 
Statistical analysis
Data are expressed as the mean9 S.E.M. Statistics included two-way analysis of variance (ANOVA II: factor 1=time of sampling; factor 2= diagnostic). To assess any significant difference between the groups of patients, i.e. CGD, GHPD and GLH groups, a Bonferroni test was applied. The results only showed differences between GH levels at 140 min (Fig. 2) .
Results Fig. 1 shows basal, 120 and 140 min values of melatonin after propranolol+exercise test in the three groups of patients compared with the untreated group (control). Control levels of melatonin showed a significant (PB 0.05) decrease from basal (19.79 1.1 ng/L) to 12.49 1.9 ng/L and 9.9591.6 ng/L at 120 and 140 min, respectively; this decline is typical of its circadian decay. Melatonin also decreased significantly in CGD, GLH and GHPD groups at 120 (P B0.05) and 140 (PB0.01) min after propranolol+exercise test (Fig. 1) relative to pretest levels. No significant differences were found in the basal levels of melatonin among the groups. However, melatonin levels in GLH and GHPD groups at 120 min and In humans, melatonin production by the pineal gland is mainly regulated by b-adrenergic receptors [Little et al., 1996] . Binding and quantitative autoradiographic studies have shown that b 1 -adrenergic receptors are more numerous, although b 2 -adrenergic receptors are also present [Little et al., 1996] . Some reports show that b-adrenoceptor agonists do not stimulate daytime melatonin secretion in healthy humans, although a transient increase in melatonin production after the b 2 -agonist ritodrine was found [Berlin et al., 1995] . The lack of sustained effects of b-adrenoceptor agonists on melatonin production could be due to the low doses of b-adrenoceptor agonists used. By contrast, propranolol and the b 1 -adrenergic antagonist atenolol produced a similar blocking effect on melatonin production in humans [Walker et al., 1996; Nathan et al., 1997] . These data, and those obtained in a recent study measuring the influence of specific b-blockade on melatonin production in humans, have revealed that b-blockers decrease melatonin release via specific inhibition of adrenergic b 1 -receptors [Stoschitzky et al., 1999] . The differences in the effects of agonists and/or antagonists of the b-adrenoceptors on melatonin production may also be due to the purity of the drugs including the enantiomer used and its intrinsic sympathomimetic activity [Stoschitzky et al., 1999] . The effect of b-adrenoceptor blockade treatment on melatonin levels persists when treatment continues [Cowen et al., 1985] , and it may have clinical implications.
Propranolol is a well-known stimulus to GH production and together with exercise it constitutes an extensive test used to evaluate the hypophyseal production of GH in children suspected of GH deficiency. In our hands, GH significantly increased at 140 min after the test was started, reflecting a hypophyseal release of GH. The GH response in the GHPD group was lower than in CGD and GLH groups, suggesting a partial deficit of GH in the former.
GH exhibits a reported association with melatonin in humans. In vitro GH augmented pineal melatonin content [Cardinali et al., 1987] , whereas melatonin reduced both the basal production and secretion of pituitary GH [Griffiths et al., 1987] . However, exercise-induced GH is enhanced by melatonin [Meeking et al., 1999] . Stimulation of GH, due to insulin hypoglycemia, arginine infusion [Gupta et al., 1983] , or GHRH administration [Gupta, 1986] was consistently associated with the inhibition of circulating melatonin. Although it was suggested that melatonin suppresses human GH secretion at least partially by its antiserotonin activity [Smythe and Lazarus, 1974] , melatonin levels in CGD, GLH and GHPD groups at 140 min were significantly lower than those in their respective control groups at these times (PB 0.05). Fig. 2 shows basal, 120 and 140 min values of GH after the propranolol+exercise test in the three groups of patients compared with the untreated group (control). Control levels of GH did not change over the time of the experiment (basal, 2.29 0.2 ng/mL; 120 min, 1.990.3 ng/mL; 140 min, 2.39 0.2 ng/mL). At 120 min, GH levels in CGD group increased significantly (PB 0.05). At 140 min, GH levels reached their highest values (PB 0.001 compared with basal and 120 min). At this time, however, the levels of GH in GHPD group were significantly lower (PB 0.01) than those in CGD and GLH groups.
Discussion
The results of this study demonstrate that propranolol, an unspecific b-blocking drug, significantly reduced the levels of melatonin in children subjected to exercise, a stimulus reported to induce melatonin secretion [Carr et al., 1981] . The first consideration to take into account from these results is the time at which the test was applied. From 09:00 to 11:20 hr, i.e. 140 min after the test when the last blood sample was taken, melatonin levels are usually declining due to its circadian rhythm [Kennaway et al., 1999] . Although a possible phase-shifting effect of chronic exercise on melatonin rhythm was suggested [van Cauter et al., 1993] , it is an unlikely confounder in the present study due to the duration and time of day at which the experiment was performed. Also, the results indicate that the circadian decay of melatonin was significantly different of the production seen during the applied test, thus suggesting a specific effect of propranolol and/or exercise in these patients.
other studies support that an interaction between GH and melatonin might operate through somatostatinergic pathways, with reciprocal negative feedback regulation. In fact, administration of the somatostatin analogue octreotide significantly reduced GH and restored the circadian melatonin rhythm in acromegalic patients [Sinisi et al., 1997] . Idiopathic GH deficiency has been associated with the absence of a melatonin circadian rhythm in humans and our results show that GHPH patients have lower melatonin levels than CGD and GLH subjects.
It seems that in normal healthy individuals it is more difficult to identify a relationship between melatonin and GH [Rao and Mager, 1987] . Oral melatonin treatment was without effect on GH in adults [Kostoglu-Athanassiou et al., 1998 ], although in children it produced a significant decrease in GH levels [Lissoni et al., 1986] . However, large doses of i.v. melatonin can stimulate GH production in adults [Esposti et al., 1988] . Melatonin administration enhanced both the basal and GHRH-stimulated GH release through the same pathways as pyridostigmine, presumably through a hypothalamic mechanism inhibiting endogenous somatostatin release [Valcavi et al., 1993] , and these results may explain the lack of effect of melatonin on the GH response in pituitary tumors [Lissoni et al., 1992] . However, in contrast to pyridostigmine, the action of melatonin may be exerted through an opioid mechanism [Coiro et al., 1998 ], a process also involved in other central actions of the indoleamine [Gomar et al., 1993] .
In hypothalamic -pituitary dysfunction, the relationships between melatonin and GH are more apparent. Melatonin production increased in hypogonadotrophic hypogonadism, and treatment with atenolol was associated with suppression of nocturnal melatonin secretion but a brisk rebound in the morning and a considerably delayed peak excretion time [Walker et al., 1996] . Administration of propranolol decreased melatonin [Mayeda et al., 1998 ] and restored the gonadotropin response to gonadotropin-releasing hormone in anorexia [Pawlikowski and Zarzycki, 1999] . Thus, the impairment of the hypothalamic -pituitary axis depends, at least partially, on increased sensitivity to endogenous melatonin.
In our results, we do not find a correlation between melatonin and GH in any group. One explanation may come from the interpretation of the changes in melatonin during the test. In fact, one could assume that after exercise, melatonin levels increased since the dose of propranolol used was not sufficient to block all melatonin secretion. In another experiment from our laboratory, we found that, after vigorous exercise performed under controlled conditions in healthy subjects, melatonin levels also decreased (unpublished observations). Since exercise increases oxygen consumption and free-radical production, one can suppose that melatonin decreases by scavenging oxygen radicals [Hara et al., 1996 [Hara et al., , 1997 . In humans, it is known that the total antioxidant capacity of serum correlates with the levels of melatonin [Benot et al., 1999] . Thus, it will be of great interest to measure the levels of melatonin metabolites produced by its antioxidant activity, i.e. N-acetyl-5-methoxykynurenamine [Hirata et al., 1974; Hardeland et al., 1995] and the recently described cyclic 3-hydroxymelatonin [Tan et al., 1998 ] in situations similar to those described in this paper.
To summarize, our data indicate that oral administration of propranolol to children performing a standardized exercise test increases GH release and decreases melatonin levels, and the findings that the test is useful to evaluate pineal function in children during development. Although these data may reflect a feedback regulation between these hormones, an independent effect of propranolol and/or exercise on GH production and melatonin production and/or oxidative metabolization is not precluded by these results.
